CAJ | 학술논문

目的研究乙二胺四乙酸(EDTA)依赖性假性血小板减少症(EDTA-PTCP)在肿瘤患者中的临床特征,为分析其相关因素提供资料.方法统计中山大学附属肿瘤防治中心2007年10月至2009年9月肿瘤患者中EDTA-PTCP患者的病史、肿瘤类型、治疗方法、使用药物等,分析上述因素与EDTA-PTCP的关系.结果本中心此2年约55 000例肿瘤患者中共有49例发生EDTA-PTCP,男24例(49.0%),女25例(51.0%).49例中10例(20.4%)有高血压史,5例(10.2%)有糖尿病史.共涉及17种肿瘤,每种1～11例不等.49例中13例(26.5%)在肿瘤治疗前检出EDTA-PTCP,36例(73.5%)在肿瘤治疗后榆出;36例中肿瘤治疗包括化疗11例(30.6%)、放疗+化疗5例(13.9%)、肿瘤切除15例(41.7%)、介入治疗5例(13.9%);16例化疗患者中,地塞米松使用最多(87.5%,14/16);20例手术患者(包括肿瘤切除15例、介入治疗5例)中青霉素类抗生素使用最多(75.0%,15/20).18例(36.7%)检出1次EDTA-PTCP;31例(63.3%)检出2次以上,EDTA-PTCP持续时间≤2周的有35例.根据疗程长短分为2组,肿瘤切除与未治疗组(28例)和肿瘤化疗与介入治疗组(21例),EDTA-PTCP持续时间≤2周的患者比例在两组间差异有统计学意义(89.3%比47.6%,x2=10.22,P＜0.01).结论肿瘤患者中EDTA-PTCP的发生与性别、合并常见病、肿瘤类型及治疗方式可能无关,与治疗用药可能有关;EDTA-PTCP持续时间与疗程长短可能有关.
목적 연구을이알사을산(EDTA)의뢰성가성혈소판감소증(EDTA-PTCP)재종류환자중적림상특정,위분석기상관인소제공자료.방법 통계중산대학부속종류방치중심2007년10월지2009년9월종류환자중EDTA-PTCP환자적병사、종류류형、치료방법 、사용약물등,분석상술인소여EDTA-PTCP적관계.결과 본중심차2년약55 000례종류환자중공유49례발생EDTA-PTCP,남24례(49.0%),녀25례(51.0%).49례중10례(20.4%)유고혈압사,5례(10.2%)유당뇨병사.공섭급17충종류,매충1～11례불등.49례중13례(26.5%)재종류치료전검출EDTA-PTCP,36례(73.5%)재종류치료후유출;36례중종류치료포괄화료11례(30.6%)、방료+화료5례(13.9%)、종류절제15례(41.7%)、개입치료5례(13.9%);16례화료환자중,지새미송사용최다(87.5%,14/16);20례수술환자(포괄종류절제15례、개입치료5례)중청매소류항생소사용최다(75.0%,15/20).18례(36.7%)검출1차EDTA-PTCP;31례(63.3%)검출2차이상,EDTA-PTCP지속시간≤2주적유35례.근거료정장단분위2조,종류절제여미치료조(28례)화종류화료여개입치료조(21례),EDTA-PTCP지속시간≤2주적환자비례재량조간차이유통계학의의(89.3%비47.6%,x2=10.22,P＜0.01).결론 종류환자중EDTA-PTCP적발생여성별、합병상견병、종류류형급치료방식가능무관,여치료용약가능유관;EDTA-PTCP지속시간여료정장단가능유관.
Objective To investigate the correlation factors of ethylenediaminetetraacetic aciddependent pseudothrombocytopenia (EDTA-PTCP) in cancer patients. Methods The potential correlation factors of EDTA-PTCP such as gender, age, case history, tumor types, therapeutic drugs and duration of EDTA-PTCP from cancer patients were analyzed based on the patient records from October 2007 to September 2009 at our cancer center. Results A total of 49 EDTA-PTCP cases from a pool of 55 000 cancer patients were collected. No correlation was found with gender( male 49. 0%, female 51.0% ), concurrent hypertension(20. 4% )/diabetes( 10. 2% ) or cancer types( 1 - 11 cases each type). EDTA-PTCP appeared at pre-therapy ( n = 13 ) and post-therapy ( n = 36). Eleven cases( 30. 6% ) were chemotherapy, 5 cases ( 13.9% ) were radiotherapy plus chemotherapy, 15 case(41.7% )were tumor resection, 5 cases( 13.9% ) were interventional therapy in 36 patients whose EDTA-PTCP appeared post-therapy. The mose frequence use in chemotherapy patients was dexamethasone(87. 5%, 14/16), and in surgery patients was penicillin antibiotics(75.0%, 15/20). And its frequency was once ( n = 18) and more than twice ( n = 31 ). If the subjects were divided into 2 groups of non-treatment plus surgery and chemotherapy plus intervention on the basis of treatment course, there was a significant difference between two groups in proportion of patients whose duration of EDTA-PTCP ≤2 weeks (89. 3% vs 47. 6% ,x2 = 10. 22, P ＜0. 01). Conclusions The incidence of EDTA-PTCP in cancer patients may be associated with therapeutic drugs, but not probably with gender,concurrent hypertension/diabetes, tumor types or therapeutic regimens. Duration of EDTA-PTCP may be associated with the treatment course.